SCYNEXIS Company Profile (NASDAQ:SCYX)

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings data on Monday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.52) by $0.04. The company earned $0.06 million during the quarter. SCYNEXIS had a negative net margin of 11,148.09% and a negative return on equity of 69.47%. View SCYNEXIS's Earnings History.

8 brokers have issued 1-year price targets for SCYNEXIS's stock. Their predictions range from $7.00 to $16.00. On average, they expect SCYNEXIS's stock price to reach $11.19 in the next twelve months. View Analyst Ratings for SCYNEXIS.

Here are some recent quotes from research analysts about SCYNEXIS stock:

• 1. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (7/12/2017)
• 2. Guggenheim analysts commented, "Post 4Q16, we remain positive on SCYX because we believe SCY-078 still has a viable future and is differentiated as a potential IV-oral stepdown therapy for invasive fungal infections, an area of unmet need that is difficult to treat. While the delay in the IV formulation is not ideal, SCYX was not going to move forward with the high doses where the thrombotic events were experienced. SCYX will meet the FDA in 2Q17 to discuss a path forward for the IV formulation. Importantly, oral SCY-078 development is not affected, and SCYX continues to move forward with the rest of its pipeline assets as well." (3/14/2017)
• 3. Needham & Company LLC analysts commented, "Scynexis announced late yesterday that FDA has placed a clinical hold on IV SCY-078. Oral program is not affected. Mgmt disclosed yesterday there were three mild-moderate catheter-site thrombotic events in the previously completed IV SCY-078 Phase 1 trial in healthy volunteers. These events were associated with the highest doses and highest concentrations tested in the trial. Mgmt stated these doses are higher than needed for efficacy based on preclinical and clinical PK/PD data and the company had proposed a lower dose for Phase 2 and 3 development. Mgmt plans to meet with FDA in 2Q17 to review safety profile and rationale for dose selection. Based on available information, our bias is that this issue can be resolved w/o changes or w/ administration of lower concentration of drug and/or longer administration time. It is possible clinical hold may result in only one quarter delay (Phase 2 initiation had been expected 1Q17). However, we note there is a risk the FDA may determine IV SCY-078 therapeutic window is not wide enough, resulting in delays (develop alternative formulations; additional PK/PD work; changes to administration regimen) or an end to IV program. We believe the latter is unlikely." (3/3/2017)
• 4. HC Wainwright analysts commented, "Treatment landscape improved, but inflammation persists: We initiated our discussion covering the positive impact of CFTR modulating therapies Kalydeco and Orkambi, which have established significant improvements in a small set of CF patients and more modest improvement across the broader CF population, respectively. Corbus’ Phase 2 CF study allows for patients on stable regimens of Orkambi or Kalydeco, whose benefit has been reached by the time they enter the Corbus trial." (2/22/2017)
• 5. Aegis analysts commented, "We are initiating coverage of Scynexis with a Buy rating and a price target of $7 per share. Scynexis is a clinical stage biotechnology company developing a new class of anti-fungal drugs. The lead molecule, SCY-078, has the same target as the current echinocandin class but can be formulated for both oral or intravenous administration. It is a structurally different molecule with different pharmacological properties and not simply an oral version of an existing drug. Clinical testing has shown SCY-078 has a broader spectrum of activity than the current echinocandins, including efficacy against the mutated fungal strains that resist treatment and are making the current drugs ineffective." (1/31/2017)

Some companies that are related to SCYNEXIS include Intellipharmaceutics International (IPCI), Concordia International Corp. (CXRX), Diurnal Group PLC (DNL), Innocoll Holdings (INNL), Neuralstem (CUR), Juniper Pharmaceuticals (JNP), Amryt Pharma PLC (AMYT), Pernix Therapeutics Holdings (PTX), Histogenics Corporation (HSGX), BioLife Solutions (BLFS), Evoke Pharma (EVOK), Marinus Pharmaceuticals (MRNS), Immune Pharmaceuticals (IMNP), Eyegate Pharmaceuticals (EYEG), Venture Life Group PLC (VLG), Galena Biopharma (GALE), Apricus Biosciences (APRI) and Aegerion Pharmaceuticals (AEGR).

SCYNEXIS's management team includes the folowing people:

• Pamela J. Kirby Ph.D., Chairman of the Board
• Marco Taglietti M.D., President, Chief Executive Officer, Director
• Eric S. Francois, Chief Financial Officer
• David Angulo M.D., Chief Medical Officer
• Laurent Arthaud, Director
• Steven C. Gilman Ph.D., Director
• Ann F. Hanham Ph.D., Director
• David C. Hastings, Director
• Patrick J. Langlois Ph.D., Director

Shares of SCYNEXIS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SCYNEXIS stock can currently be purchased for approximately $1.80.